Cardiac gene editing holds promising potential in revolutionizing the landscape of cardiovascular medicine. This innovative field involves precisely modifying the genetic code within cardiac cells to address and rectify underlying genetic factors contributing to heart diseases. By leveraging advanced molecular tools such as CRISPR-Cas9, researchers aim to target specific genes associated with cardiac conditions, paving the way for personalized therapeutic interventions. The ability to edit genes directly in cardiac tissue opens new avenues for treating congenital heart disorders, genetic predispositions, and other cardiovascular ailments. While still in the early stages of development, cardiac gene editing represents a cutting-edge approach that holds great promise for advancing our understanding of cardiac health and fostering breakthroughs in tailored treatments for individuals with various cardiovascular conditions.
Title : Frequency of residual risk in cardiovascular secondary prevention in patients treated at the Reina Fabiola University Clinic
Agustin Joison, Cordoba Catholic University, Argentina
Title : Revolutionizing heart health through Personalized & Precision Medicine (PPM): Towards personalized cardiovascular prevention, precision cardiac care & rehabilitation via optimizing Cardiac Hospital Networks
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Antibody-proteases as unique biomarkers, potential targets and translational tools of the next step generation to be used in personalized and precision cardiology practice
Sergey Suchkov, N. D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
Title : Investigation of bergapten’s pharmacological activity against doxorubicin induced cardiotoxicity: supporting evidence from cellular and animal models
Bijoy Krishna Banik, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, India